Abstract
Despite advances in screening approaches for prostate cancer, it is anticipated that 28,000 men will die of the disease this year in the United States alone. This highlights a need for more effective imaging technologies for staging, monitoring, and treatment planning of prostate cancer. ProstaScint is the only FDA-approved targeted-imaging agent for prostate cancer. However, its clinical utility is limited by low specificity and sensitivity. We describe a novel targeted imaging agent based on an RNA aptamer (A10-3.2) conjugated to a chelator (DOTA) housing an indium-111 radionuclide for SPECT/CT imaging.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
